Another Distinct Major New Study Confirms the Benefits of Statins in Reducing Risk of Alzheimer's Disease.Business Editors/Health/Medical Writers MAYWOOD, N.J.--(BUSINESS WIRE)--April 29, 2004 Nymox Pharmaceutical Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :NYMX NYMX New York Mercantile Exchange ) Has Global Patent Rights for the Use of Statin Drugs for the Treatment and Prevention of Alzheimer's Disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. For the second time this week, a separate new study presented at the 56th Annual Meeting of the American Academy of Neurology The American Academy of Neurology (AAN) is a professional society for neurologists and neuroscientists. As a medical specialty society it was established in 1949 by A.B. Baker of the University of Minnesota to advance the art and science of neurology, and thereby promote the best provides important new evidence that taking statins Statins A class of drugs commonly used to lower LDL cholesterol levels. Mentioned in: C-Reactive Protein , commonly prescribed cholesterol-lowering medication, can significantly reduce the risk of Alzheimer's disease, according to Dr. Michael Munzar, Medical Director of Nymox Pharmaceutical Corporation. Researchers with the Canadian Collaborative Cohort of Related Dementias (ACCORD) Study found that taking statins reduced the risk of acquiring Alzheimer's disease by 52% for the study group as a whole and by 77% for those study subjects who were not ApoE-4 carriers. The ACCORD Study followed 1136 patients who had been referred to dementia research clinics with the large majority initially showing symptoms of cognitive impairment. The study, "Interaction between Statin stat·in n. Any of a class of drugs that inhibit a key enzyme involved in the synthesis of cholesterol and promote receptor binding of LDL cholesterol, resulting in decreased levels of serum cholesterol. Usage and Apolipoprotein E apolipoprotein E A 34-kD cholesterol-binding glycoprotein, which comprises 15% of VLDL; apoE maps to chromosome 19, is secreted by macrophages that mediate the uptake of lipoproteins–VLDL, HDL, LDL and cholesterol esters into cells via distinct binding Genotype in Risk of Developing Alzheimer's Disease: Data from the ACCORD Study" was authored by Ging-Yuek R. Hsiung, Leila Shobab, Jacob Grand, and Howard Feldman of the ACCORD Study Group (P03.053). Dr. Munzar said, "This study is significant because of its large size and because of the substantial reduction in the risk of acquiring Alzheimer's disease found for patients on statins. The case is very compelling." Nymox holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of AD. Scientific and clinical studies have shown the potential benefits of statin drugs to prevent or treat AD. Studies have shown up to 70% reduction in AD incidence in individuals who use statin drugs. Recent studies include, for example, International Journal of Geriatric Psychiatry 2004;19:327-32; Neuroepidemiology 2004; 23:94-8; Neuron 2004; 41:7-10; Arch Neurol 2000; 57:1439-1443; Lancet 2000; 356:1627-1631; Arch Neurol 2002; 59:223-227; J Gerontol Biol Sci Med Sci 2002;57:M414-M418; and J Am Geriatr Soc 2002;50:1852-1856. The current global market for statins is estimated at $19 billion per year and to be growing at 15% per year. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting af·flict tr.v. af·flict·ed, af·flict·ing, af·flicts To inflict grievous physical or mental suffering on. [Middle English afflighten, from afflight, an estimated 4.5 million people in the U.S. More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion